Cullinan Therapeutics (CGEM) Assets Average (2021 - 2026)

Cullinan Therapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $425.7 million for Q1 2026.

• In Q1 2026, Assets Average fell 29.14% year-over-year to $425.7 million; the TTM figure through Mar 2026 stood at $425.7 million (down 29.14% YoY), while the FY2025 annual figure was $535.1 million, down 3.24% from the prior year.
• Assets Average for Q1 2026 stood at $425.7 million, down from $466.2 million in the prior quarter.
• The five-year high for Assets Average was $667.2 million in Q3 2024, with the low at $425.7 million in Q1 2026.
• The 5-year median for Assets Average is $538.1 million (2023), against an average of $538.7 million.
• The sharpest annual moves came in 2022 and 2026: Assets Average jumped 39.96% in 2022, then dropped 29.14% in 2026.
• Cullinan Therapeutics' Assets Average stood at $589.2 million in 2022, then slipped by 16.93% to $489.4 million in 2023, then jumped by 30.26% to $637.5 million in 2024, then decreased by 26.87% to $466.2 million in 2025, then dropped by 8.7% to $425.7 million in 2026.
• Business Quant data shows CGEM's Assets Average at $425.7 million in Q1 2026, $466.2 million in Q4 2025, and $502.2 million in Q3 2025.